The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.

Kiyotaka Yoh, Kōichi Goto, Kei Kunimasa et al.|Journal of Clinical Oncology|2019

Cited by 5